Antifibrotic agent 1

Antifibrotic agent 1 is an orally active anti-idiopathic pulmonary fibrosis (IPF) agent. Antifibrotic agent 1 effectively attenuates IPF-related processes, including TGF-β induced EMT and FMT processes, as well as pro-fibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α and Src family kinases (SFKs), while sparing VEGFRs, FGFRs and Abl to minimize off-target toxicity. Antifibrotic agent 1 has potent anti-fibrotic activity in Bleomycin (BLM) (HY-108345) -induced pulmonary fibrosis mice model[1].

Product Specifications

UNSPSC

12352005

Target

C-Fms; Collagen; PDGFR; Src

Related Pathways

Cytoskeleton; Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

CC(NC1=CC=C(C(Cl)=C1)NC(C2=CC=C(C(C#CC3=CC(C4=CN(N=C4)C)=CN=C3N)=C2)C)=O)=O

Molecular Formula

C27H23ClN6O2

Molecular Weight

498.96

References & Citations

[1]Chen X, et al. Design, synthesis, and biological evaluation of N- (2-amino-phenyl) -5- (4-aryl-pyrimidin-2-yl) amino) -1H-indole-2-carboxamide derivatives as novel inhibitors of CDK9 and class I HDACs for cancer treatment [J]. Bioorganic Chemistry, 2025: 108577.